INMB Key Statistics, Chart & Performance
The current stock price of INMB is 1.49 USD. In the past month the price decreased by -33.18%. In the past year, price decreased by -72.86%.
INMB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About INMB
Company Profile
INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 22 full-time employees. The company went IPO on 2019-02-04. The firm has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
Company Info
INMUNE BIO INC
225 Ne Mizner Blvd, Suite 640
Boca Raton FLORIDA 92037 US
CEO: Raymond J. Tesi
Employees: 18
Phone: 18589643720
INMUNE BIO INC / INMB FAQ
What does INMUNE BIO INC do?
INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 22 full-time employees. The company went IPO on 2019-02-04. The firm has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
What is the stock price of INMUNE BIO INC today?
The current stock price of INMB is 1.49 USD. The price decreased by -2.61% in the last trading session.
Does INMUNE BIO INC pay dividends?
INMB does not pay a dividend.
How is the ChartMill rating for INMUNE BIO INC?
INMB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for INMUNE BIO INC?
INMUNE BIO INC (INMB) operates in the Health Care sector and the Biotechnology industry.
Would investing in INMUNE BIO INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INMB.
What is the Short Interest ratio of INMUNE BIO INC (INMB) stock?
The outstanding short interest for INMUNE BIO INC (INMB) is 15.51% of its float.
INMB Technical Analysis
INMB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to INMB. The financial health of INMB is average, but there are quite some concerns on its profitability.
INMB Financial Highlights
Over the last trailing twelve months INMB reported a non-GAAP Earnings per Share(EPS) of -2.12. The EPS increased by 2.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -149.55% | ||
| ROE | -196.58% | ||
| Debt/Equity | 0 |
INMB Forecast & Estimates
10 analysts have analysed INMB and the average price target is 5.36 USD. This implies a price increase of 259.4% is expected in the next year compared to the current price of 1.49.
For the next year, analysts expect an EPS growth of 7.18% and a revenue growth 376.19% for INMB